Comparison Of Efficacy Between DEB-TACE And CTACE In Advanced Hepatic Malignant Tumors

Objective : Hepatic artery chemoembolization(Transarterial chemoembolizatin,conventional TACE)is the commonly used methods of interventional treatment of primary liver cancer,compared with surgical resection,small trauma,rapid recovery,etc,is similar to surgical resection for small hepatocellular carcinoma even treatment effect,apply to a lost surgery to remove the middle-late patients or elderly patients can't tolerate surgery.With the wide application and development of hepatic arterial chemoembolization technology,the Drug-eluting beads(DEB)has emerged as a new type of embolic agent.However,the evaluation of its therapeutic effect and postoperative reaction is not the same at home and abroad.In this paper,the efficacy and safety of DEB-TACE and cTACE in the treatment of advanced malignancies,especially the large block type hepatocellular carcinoma and diffuse liver cancer,were analyzed.Methods:Collected from 2016 to 2017,a total of two years to surgical resection of liver in patients with malignant tumor,are accepted percutaneous arterial chemoembolization,a total of 58 cases,using the carrier drug microsphere embolization agent(Calispheres or Hepaspheres)line DEB-line or used iodized oil embolism agent cTACE with conventional treatment,respectively,1 week before surgery and postoperative 1 month,3 months lier enhanced CT or MR images,enhanced the same period and improve the blood biochemical examination.The imaging and clinical data of the patients were followed up,and mRICIST was used to evaluate the efficacy of solid tumors,and the differences between the two types of embolic agents in postoperative complications and adverse reactions were compared.Results:The tumor remission rate was 76.2% and 75.0%(P>0.05),and the tumor control rate was 81.0% and 93.8%(P > 0.05).The tumor remission rate was 73.8%and 75.0%(P > 0.05),and the tumor control rate was 78.6% and 87.5%(P > 0.05).Adverse reactions and complications in cTACE group,fever(19.0%),abdominal pain(26.2%),nausea and vomiting(16.7%),severe complications(0%).Adverse reactions and complications of DEB-TACE group,fever(18.8%),abdominal pain(43.8%),nausea and vomiting(25.0%),severe complications(12.5%).In the cTACE group and DEB-TACE group,platelet,albumin,ALT,AST,total bilirubin,tumor markers and creatinine were compared before and after the operation.P > 0.05.Conclusion:Compared with cTACE group,there was no significant difference in tumor response between 1~3 months after surgery,and it was safe and effective in the treatment of tumor.